Rockwell Automation vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Rockwell Automation trades at $436.4 (market cap $48.21B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.4 (market cap $2.27B). The key difference: Rockwell Automation is far larger — about 21.2× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Rockwell Automation pays a 1.27% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ROK | SLS | |
|---|---|---|
Market Cap | $48.21B | $2.27B |
Volume | 953,342 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $495.08 | $15.46 |
52-Week Low | $333.75 | $1.39 |
Typical Hold Time | 74 Days | — |
Enterprise Value | $51.34B | $2.14B |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $441.9, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $489.89 implying 11% upside. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending, and maintains strong profitability with a 13.38% net income margin and 34.47% ROE. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms.
ROK presents a growth opportunity driven by automation demand and digital transformation trends, but faces risks from high valuation multiples (P/E 41.38) and cyclical industrial spending. Analyst sentiment is mixed with 68% hold ratings, reflecting caution amid solid fundamentals. Investors should weigh earnings consistency against premium pricing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →